Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage

Kyung Ho Yu, Keun Sik Hong, Mi Sun Oh, Juneyoung Lee, Ji Sung Lee, Sun U. Kwon

Research output: Contribution to journalArticle

Abstract

Goal Cognitive impairment and dementia are common disabilities after stroke and are associated with increased risks of mortality and recurrent stroke. The prevention of dementia and preserving cognitive function are also important in stroke patients, but its strategy is not established yet. This PICASSO-COG (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage for reducing COGnitive decline) substudy aims to assess the effects of cilostazol and/or probucol on cognitive function. Materials and methods The substudy aims to assess the reduction in cognitive decline of patients treated with cilostazol and/or probucol in the PICASSO trial. Patients will be assessed using the Korean version of mini-mental state examination and Montreal Cognitive Assessment at 4, 7, 10, 13, 25, 37, and 49 months after randomization. The primary outcome is the change in mini-mental status examination score, compared between treatment groups, with a modified intention-to-treat population using a restricted maximum likelihood-based mixed effects model repeat measurement. This will allow a within-subject correlation due to repeated cognitive tests as well as a different number of measurements among subjects at baseline and each follow-up period. Conclusion PICASSO-COG is a novel study for assessing the effect on cognitive function of different antiplatelet regimens and the addition of a nonstatin lipid-lowering agent to the current standard statin therapy in patients who have a recent ischemic lesion and prior intracerebral macro- or microbleeds.

Original languageEnglish
Pages (from-to)2061-2066
Number of pages6
JournalJournal of Stroke and Cerebrovascular Diseases
Volume25
Issue number8
DOIs
Publication statusPublished - 2016 Aug 1

Fingerprint

Cerebral Hemorrhage
Stroke
Probucol
Cognition
Dementia
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Random Allocation
Lipids
Mortality
Therapeutics
Population
Cognitive Dysfunction
cilostazol

Keywords

  • cerebral infarction
  • cilostazol
  • clinical trial
  • Cognitive impairment
  • intracerebral hemorrhage
  • microbleeds
  • probucol
  • vascular dementia

ASJC Scopus subject areas

  • Surgery
  • Rehabilitation
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage. / Yu, Kyung Ho; Hong, Keun Sik; Oh, Mi Sun; Lee, Juneyoung; Lee, Ji Sung; Kwon, Sun U.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 25, No. 8, 01.08.2016, p. 2061-2066.

Research output: Contribution to journalArticle

@article{6debb3fd92374482aaa36b0122f4bd65,
title = "Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage",
abstract = "Goal Cognitive impairment and dementia are common disabilities after stroke and are associated with increased risks of mortality and recurrent stroke. The prevention of dementia and preserving cognitive function are also important in stroke patients, but its strategy is not established yet. This PICASSO-COG (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage for reducing COGnitive decline) substudy aims to assess the effects of cilostazol and/or probucol on cognitive function. Materials and methods The substudy aims to assess the reduction in cognitive decline of patients treated with cilostazol and/or probucol in the PICASSO trial. Patients will be assessed using the Korean version of mini-mental state examination and Montreal Cognitive Assessment at 4, 7, 10, 13, 25, 37, and 49 months after randomization. The primary outcome is the change in mini-mental status examination score, compared between treatment groups, with a modified intention-to-treat population using a restricted maximum likelihood-based mixed effects model repeat measurement. This will allow a within-subject correlation due to repeated cognitive tests as well as a different number of measurements among subjects at baseline and each follow-up period. Conclusion PICASSO-COG is a novel study for assessing the effect on cognitive function of different antiplatelet regimens and the addition of a nonstatin lipid-lowering agent to the current standard statin therapy in patients who have a recent ischemic lesion and prior intracerebral macro- or microbleeds.",
keywords = "cerebral infarction, cilostazol, clinical trial, Cognitive impairment, intracerebral hemorrhage, microbleeds, probucol, vascular dementia",
author = "Yu, {Kyung Ho} and Hong, {Keun Sik} and Oh, {Mi Sun} and Juneyoung Lee and Lee, {Ji Sung} and Kwon, {Sun U.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.jstrokecerebrovasdis.2016.04.028",
language = "English",
volume = "25",
pages = "2061--2066",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage

AU - Yu, Kyung Ho

AU - Hong, Keun Sik

AU - Oh, Mi Sun

AU - Lee, Juneyoung

AU - Lee, Ji Sung

AU - Kwon, Sun U.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Goal Cognitive impairment and dementia are common disabilities after stroke and are associated with increased risks of mortality and recurrent stroke. The prevention of dementia and preserving cognitive function are also important in stroke patients, but its strategy is not established yet. This PICASSO-COG (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage for reducing COGnitive decline) substudy aims to assess the effects of cilostazol and/or probucol on cognitive function. Materials and methods The substudy aims to assess the reduction in cognitive decline of patients treated with cilostazol and/or probucol in the PICASSO trial. Patients will be assessed using the Korean version of mini-mental state examination and Montreal Cognitive Assessment at 4, 7, 10, 13, 25, 37, and 49 months after randomization. The primary outcome is the change in mini-mental status examination score, compared between treatment groups, with a modified intention-to-treat population using a restricted maximum likelihood-based mixed effects model repeat measurement. This will allow a within-subject correlation due to repeated cognitive tests as well as a different number of measurements among subjects at baseline and each follow-up period. Conclusion PICASSO-COG is a novel study for assessing the effect on cognitive function of different antiplatelet regimens and the addition of a nonstatin lipid-lowering agent to the current standard statin therapy in patients who have a recent ischemic lesion and prior intracerebral macro- or microbleeds.

AB - Goal Cognitive impairment and dementia are common disabilities after stroke and are associated with increased risks of mortality and recurrent stroke. The prevention of dementia and preserving cognitive function are also important in stroke patients, but its strategy is not established yet. This PICASSO-COG (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage for reducing COGnitive decline) substudy aims to assess the effects of cilostazol and/or probucol on cognitive function. Materials and methods The substudy aims to assess the reduction in cognitive decline of patients treated with cilostazol and/or probucol in the PICASSO trial. Patients will be assessed using the Korean version of mini-mental state examination and Montreal Cognitive Assessment at 4, 7, 10, 13, 25, 37, and 49 months after randomization. The primary outcome is the change in mini-mental status examination score, compared between treatment groups, with a modified intention-to-treat population using a restricted maximum likelihood-based mixed effects model repeat measurement. This will allow a within-subject correlation due to repeated cognitive tests as well as a different number of measurements among subjects at baseline and each follow-up period. Conclusion PICASSO-COG is a novel study for assessing the effect on cognitive function of different antiplatelet regimens and the addition of a nonstatin lipid-lowering agent to the current standard statin therapy in patients who have a recent ischemic lesion and prior intracerebral macro- or microbleeds.

KW - cerebral infarction

KW - cilostazol

KW - clinical trial

KW - Cognitive impairment

KW - intracerebral hemorrhage

KW - microbleeds

KW - probucol

KW - vascular dementia

UR - http://www.scopus.com/inward/record.url?scp=84973861020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973861020&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2016.04.028

DO - 10.1016/j.jstrokecerebrovasdis.2016.04.028

M3 - Article

VL - 25

SP - 2061

EP - 2066

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 8

ER -